Upstream Bio, INC Form 4 insider transactions

Aaron Deykin, Chief Medical Officer of Upstream Bio, Inc., was granted stock options for 165,000 shares of common stock on February 6, 2025, according to a Form 4 filing.

Allison Ambrose, General Counsel of Upstream Bio, Inc., was granted stock options for 25,000 shares on February 6, 2025, according to a Form 4 filing.

Upstream Bio's General Counsel, Allison Ambrose, was granted 100,000 stock options on December 16, 2024.

Director Erez Chimovits reports conversion of preferred stock and acquisition of common stock following Upstream Bio's initial public offering.

OrbiMed Advisors and related entities report changes in beneficial ownership of Upstream Bio, Inc. common stock following the company's initial public offering.

AI Upstream LLC, along with related entities and Len Blavatnik, reported the conversion of preferred stock to common stock in Upstream Bio, Inc. following the company's initial public offering.

Wellington Biomedical Innovation Master Investors reports the conversion of Series B redeemable convertible preferred stock into common stock of Upstream Bio, Inc. following the company's IPO.

Director Erez Chimovits of Upstream Bio, Inc. reports the acquisition of stock options exercisable for 17,096 shares of common stock.

Marcela K. Ruddy, a director at Upstream Bio, Inc., acquired stock options for 17,096 shares of common stock on October 10, 2024.

Harold Edward Fleming, a director of Upstream Bio, Inc., acquired stock options for 17,096 shares on October 10, 2024, though he disclaims beneficial ownership as he holds them for Enavate Sciences, LP.

Ronald C Renaud JR, a director at Upstream Bio, Inc., acquired stock options for 17,096 shares of common stock on October 10, 2024.

Director Daniella Beckman acquired stock options for 34,681 shares of Upstream Bio, Inc. on October 10, 2024.

Director Liam Ratcliffe of Upstream Bio, Inc. reports the acquisition of stock options.